Polymyxin combination therapy for multidrug-resistant, extensively-drug resistant, and difficult-to-treat drug-resistant gram-negative infections: is it superior to polymyxin monotherapy?

References

• O’Neill J. Review on antimicrobial resistance. Tackling drugresistant infections globally: final report and recommendations. 2016. [cited 2019 Jan 10]. Available from: http://www.amrreview.org/sites/default/files/160525_Final%20paper_with%20cover.pdf
   Google Scholar
• Magiorakos A-P, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268–281.
   PubMed Web of Science ®Google Scholar
• Kadri SS, Adjemian J, Lai YL, et al. Difficult-to-treat resistance in Gram-negative bacteremia at 173 US hospitals: retrospective cohort analysis of prevalence, predictors, and outcome of resistance to all first-line agents. Clin Infect Dis. 2018;67(12):1803–1814.
   PubMed Web of Science ®Google Scholar
• Murray CJ, Ikuta KS, Sharara F, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629–655.
   PubMed Web of Science ®Google Scholar
• Lari AR, Ardebili A, Hashemi A. AdeR-AdeS mutations & overexpression of the AdeABC efflux system in ciprofloxacin-resistant Acinetobacter baumannii clinical isolates. Indian J Med Res. 2018;147(4):413.
   PubMedGoogle Scholar
• Mehrad B, Clark NM, Zhanel GG, et al. Antimicrobial resistance in hospital-acquired Gram-negative bacterial infections. Chest. 2015;147(5):1413–1421.
   PubMed Web of Science ®Google Scholar
• Peleg AY, Hooper DC. Hospital-acquired infections due to gram-negative bacteria. N Engl J Med. 2010;362(19):1804–1813.
   PubMed Web of Science ®Google Scholar
• Roshani M, Goudarzi H, Hashemi A, et al. Detection of IS903, IS26 and ISEcp1 elements in CTX-M-Producing Klebsiella pneumoniae and Escherichia coli isolates from patients with leukemia in Iran. Jundishapur J Microbiol. 2018;11(12):1–8.
   Google Scholar
• Pournajaf A, Razavi S, Irajian G, et al. Integron types, antimicrobial resistance genes, virulence gene profile, alginate production and biofilm formation in Iranian cystic fibrosis Pseudomonas aeruginosa isolates. Infez Med. 2018;26(3):226–236.
   PubMedGoogle Scholar
• Nation RL, Li J, Cars O, et al. Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus. Lancet Infect Dis. 2015;15(2):225–234.
   PubMed Web of Science ®Google Scholar
• Bergen PJ, Landersdorfer CB, Lee HJ, et al. ‘Old’ antibiotics for emerging multidrug-resistant bacteria. Curr Opin Infect Dis. 2012;25(6):626.
   PubMed Web of Science ®Google Scholar
• Hernan RC, Karina B, Gabriela G, et al. Selection of colistin-resistant Acinetobacter baumannii isolates in postneurosurgical meningitis in an intensive care unit with high presence of heteroresistance to colistin. Diagn Microbiol Infect Dis. 2009;65(2):188–191.
   PubMed Web of Science ®Google Scholar
• Moosavian M, Shoja S, Nashibi R, et al. Post neurosurgical meningitis due to colistin heteroresistant Acinetobacter baumannii. Jundishapur J Microbiol. 2014;7(10):1–5.
   Google Scholar
• Hartzell JD, Neff R, Ake J, et al. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis. 2009;48(12):1724–1728.
   PubMed Web of Science ®Google Scholar
• Dai C, Xiao X, Zhang Y, et al. Curcumin attenuates colistin-induced peripheral neurotoxicity in mice. ACS Infect Dis. 2020;6(4):715–724.
   PubMed Web of Science ®Google Scholar
• Talbot GH, Jezek A, Murray BE, et al. The infectious diseases society of America’s 10×’20 initiative (10 new systemic antibacterial agents US Food and Drug Administration approved by 2020): is 20×’20 a possibility? Clin Infect Dis. 2019;69(1):1–11.
   PubMed Web of Science ®Google Scholar
• Walsh C. Molecular mechanisms that confer antibacterial drug resistance. Nature. 2000;406(6797):775–781.
   PubMed Web of Science ®Google Scholar
• Lane D. Designer combination therapy for cancer. Nat Biotechnol. 2006;24(2):163–164.
   PubMed Web of Science ®Google Scholar
• Richman DD. HIV chemotherapy. Nature. 2001;410(6831):995–1001.
   PubMed Web of Science ®Google Scholar
• Nosten F, White NJ. Artemisinin-based combination treatment of falciparum malaria. Defining and defeating the intolerable burden of malaria. Am J Trop Med Hyg. 2007;77(6 Suppl):181–192.
   PubMed Web of Science ®Google Scholar
• Mitchison D, Davies G. The chemotherapy of tuberculosis: past, present and future. Int J Tuberc Lung Dis. 2012;16:724–732.
   PubMed Web of Science ®Google Scholar
• Tamma PD, Cosgrove SE, Maragakis LL. Combination therapy for treatment of infections with gram-negative bacteria. Clin Microbiol Rev. 2012;25(3):450–470.
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Trecarichi EM, De Rosa FG, et al. Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study. J Antimicro Chemother. 2015;70(7):2133–2143.
   PubMed Web of Science ®Google Scholar
• Gutiérrez-Gutiérrez B, Salamanca E, de Cueto M, et al. Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. Lancet Infect Dis. 2017;17(7):726–734.
   PubMed Web of Science ®Google Scholar
• Paul M, Daikos GL, Durante-Mangoni E, et al. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infect Dis. 2018;18(4):391–400.
   PubMed Web of Science ®Google Scholar
• Lenhard JR, Nation RL, Tsuji BT. Synergistic combinations of polymyxins. Int J Antimicrob Agents. 2016;48(6):607–613.
   PubMed Web of Science ®Google Scholar
• Bergen PJ, Bulman ZP, Landersdorfer CB, et al. Optimizing polymyxin combinations against resistant Gram-negative bacteria. Infect Dis Ther. 2015;4(4):391–415.
   PubMedGoogle Scholar
• Petrosillo N, Ioannidou E, Falagas M. Colistin monotherapy vs. combination therapy: evidence from microbiological, animal and clinical studies. Clin Microbiol Infect. 2008;14(9):816–827.
   PubMed Web of Science ®Google Scholar
• Ezadi F, Ardebili A, Mirnejad R. Antimicrobial susceptibility testing for polymyxins: challenges, issues, and recommendations. J Clini Microbiol. 2019;57(4):e01390–18.
   PubMedGoogle Scholar
• Gordon NC, Png K, Wareham DW. Potent synergy and sustained bactericidal activity of a vancomycin-colistin combination versus multidrug-resistant strains of Acinetobacter baumannii. Antimicrob Agents Chemother. 2010;54(12):5316–5322.
   PubMed Web of Science ®Google Scholar
• Mazutti K, Costa LB, Nascimento LV, et al. Effect of colistin and tylosin used as feed additives on the performance, diarrhea incidence, and immune response of nursery pigs. Semina: Ciências Agrárias. 2016;37(4):1947–1962.
   Google Scholar
• Jeannot K, Bolard A, Plesiat P. Resistance to polymyxins in Gram-negative organisms. Int J Antimicrob Agents. 2017;49(5):526–535.
   PubMed Web of Science ®Google Scholar
• European Centre for Disease Prevention and Control. Antimicrobial consumption in the EU/EEA (ESAC-Net)-annual epidemiological report 2021. Stockholm: ECDC; 2022. [cited 2022 Nov 20]. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/ESAC-Net_AER_2021_final-rev.pdf
   Google Scholar
• Sun S, Negrea A, Rhen M, et al. Genetic analysis of colistin resistance in Salmonella enterica serovar Typhimurium. Antimicrob Agents Chemother. 2009;53(6):2298–2305.
   PubMed Web of Science ®Google Scholar
• Simpson BW, Trent MS. Pushing the envelope: LPS modifications and their consequences. Nat Rev Microbiol. 2019;17(7):403–416.
   PubMed Web of Science ®Google Scholar
• Barrow K, Kwon DH. Alterations in two-component regulatory systems of phoPQ and pmrAB are associated with polymyxin B resistance in clinical isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2009;53(12):5150–5154.
   PubMed Web of Science ®Google Scholar
• Jayol A, Poirel L, Brink A, et al. Resistance to colistin associated with a single amino acid change in protein PmrB among Klebsiella pneumoniae isolates of worldwide origin. Antimicrob Agents Chemother. 2014;58(8):4762–4766.
   PubMed Web of Science ®Google Scholar
• Kim S-H, Jia W, Parreira VR, et al. Phosphoethanolamine substitution in the lipid A of Escherichia coli O157: H7 and its association with PmrC. Microbiology. 2006;152(3):657–666.
   PubMedGoogle Scholar
• Adams MD, Nickel GC, Bajaksouzian S, et al. Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system. Antimicrob Agents Chemother. 2009;53(9):3628–3634.
   PubMed Web of Science ®Google Scholar
• Pelletier MR, Casella LG, Jones JW, et al. Unique structural modifications are present in the lipopolysaccharide from colistin-resistant strains of Acinetobacter baumannii. Antimicrob Agents Chemother. 2013;57(10):4831–4840.
   PubMed Web of Science ®Google Scholar
• Moffatt JH, Harper M, Adler B, et al. Insertion sequence IS Aba11 is involved in colistin resistance and loss of lipopolysaccharide in Acinetobacter baumannii. Antimicrob Agents Chemother. 2011;55(6):3022–3024.
   PubMed Web of Science ®Google Scholar
• Moffatt JH, Harper M, Harrison P, et al. Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production. Antimicrob Agents Chemother. 2010;54(12):4971–4977.
   PubMed Web of Science ®Google Scholar
• Liu -Y-Y, Wang Y, Walsh TR, et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis. 2016;16(2):161–168.
   PubMed Web of Science ®Google Scholar
• Poirel L, Kieffer N, Nordmann P. In vitro study of IS Apl1-mediated mobilization of the colistin resistance gene mcr-1. Antimicrob Agents Chemother. 2017;61(7):e00127–17.
   PubMedGoogle Scholar
• Carroll LM, Gaballa A, Guldimann C, et al. Identification of novel mobilized colistin resistance gene mcr-9 in a multidrug-resistant, colistin-susceptible Salmonella enterica serotype Typhimurium isolate. MBio. 2019;10(3):e00853–19.
   PubMed Web of Science ®Google Scholar
• Wang Y, Xu C, Zhang R, et al. Changes in colistin resistance and mcr-1 abundance in Escherichia coli of animal and human origins following the ban of colistin-positive additives in China: an epidemiological comparative study. Lancet Infect Dis. 2020;20(10):1161–1171.
   PubMed Web of Science ®Google Scholar
• Al-Tawfiq JA, Laxminarayan R, Mendelson M. How should we respond to the emergence of plasmid-mediated colistin resistance in humans and animals? Int J Infect Dis. 2017;54:77–84.
   PubMed Web of Science ®Google Scholar
• Bialvaei AZ, Samadi Kafil H. Colistin, mechanisms and prevalence of resistance. Curr Med Res Opin. 2015;31(4):707–721.
   PubMed Web of Science ®Google Scholar
• Moawad AA, Hotzel H, Neubauer H, et al. Antimicrobial resistance in Enterobacteriaceae from healthy broilers in Egypt: emergence of colistin-resistant and extended-spectrum β-lactamase-producing Escherichia coli. Gut Pathog. 2018;10(1):1–12.
   PubMedGoogle Scholar
• Diekema DJ, Hsueh P-R, Mendes RE, et al. The microbiology of bloodstream infection: 20-year trends from the SENTRY antimicrobial surveillance program. Antimicrob Agents Chemother. 2019;63(7):e00355–19.
   PubMed Web of Science ®Google Scholar
• Turnidge JD, Bell JM, Jones RN. Emergence of colistin-resistant Klebsiella spp. and Enterobacter spp. in the Asia-Pacific (APAC) region: a SENTRY antimicrobial surveillance program report (2006), abstr C2-2054. Abstr. 47th Intersci. Conf Antimicrob Agents Chemother. American Society for Microbiology, Washington, DC, 2007.
   Google Scholar
• Yan W, Zhang Q, Zhu Y, et al. Molecular mechanism of polymyxin resistance in multidrug-resistant Klebsiella pneumoniae and Escherichia coli isolates from Henan province, China: a multicenter study. Infect Drug Resist. 2021;14:2657.
   PubMed Web of Science ®Google Scholar
• Khuntayaporn P, Thirapanmethee K, Chomnawang MT. An update of mobile colistin resistance in non-fermentative Gram-negative bacilli. Front Cell Infect. 2022;12(882236):1–15.
   Google Scholar
• Narimisa N, Goodarzi F, Bavari S. Prevalence of colistin resistance of Klebsiella pneumoniae isolates in Iran: a systematic review and meta-analysis. Ann Clin Microbiol. 2022;21(1):1–9.
   PubMedGoogle Scholar
• Williams PC, Isaacs D, Berkley JA. Antimicrobial resistance among children in sub-Saharan Africa. Lancet Infect Dis. 2018;18(2):e33–e44.
   PubMed Web of Science ®Google Scholar
• Maalej SM, Meziou MR, Mahjoubi F, et al. Epidemiological study of Enterobacteriaceae resistance to colistin in Sfax (Tunisia). Med Mal Infect. 2012;42(6):256–263.
   PubMedGoogle Scholar
• Dziri O, Dziri R, El Salabi AA, et al. Polymyxin E–resistant Gram-negative bacteria in Tunisia and neighboring countries: are there commonalities? Infect Drug Resist. 2021;14:4821.
   PubMed Web of Science ®Google Scholar
• Li Z, Cao Y, Yi L, et al. Emergent polymyxin resistance: end of an era? Open Forum Infect Dis. 2019;6(10):ofz368.
   PubMedGoogle Scholar
• Buess S, Nüesch-Inderbinen M, Stephan R, et al. Assessment of animals as a reservoir for colistin resistance: no MCR-1/MCR-2-producing Enterobacteriaceae detected in Swiss livestock. J Glob Antimicrob Resist. 2017;8:33–34.
   PubMedGoogle Scholar
• Li B, Ke B, Zhao X, et al. Antimicrobial resistance profile of mcr-1 positive clinical isolates of Escherichia coli in China from 2013 to 2016. Front Microbiol. 2018;9:2514.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang R, Li J, et al. Comprehensive resistome analysis reveals the prevalence of NDM and MCR-1 in Chinese poultry production. Nat Microbiol. 2017;2(4):1–7.
   Google Scholar
• Hejnar P, Kolář M, Hájek V. Characteristics of Acinetobacter strains (phenotype classification, antibiotic susceptibility and production of beta-lactamases) isolated from haemocultures from patients at the teaching hospital in Olomouc. Acta Univ Palacki Olomuc Fac Med. 1999;142:73–77.
   PubMedGoogle Scholar
• Gales AC, Jones RN, Sader HS. Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: results from the SENTRY Antimicrobial Surveillance Program (2006–09). J Antimicrob Chemother. 2011;66(9):2070–2074.
   PubMed Web of Science ®Google Scholar
• Ko KS, Suh JY, Kwon KT, et al. High rates of resistance to colistin and polymyxin B in subgroups of Acinetobacter baumannii isolates from Korea. J J Antimicrob Chemother. 2007;60(5):1163–1167.
   PubMedGoogle Scholar
• Giamarellou H. Epidemiology of infections caused by polymyxin-resistant pathogens. Int J Antimicrob Agents. 2016;48(6):614–621.
   PubMed Web of Science ®Google Scholar
• Sheck EA, Edelstein MV, Sukhorukova MV, et al. Epidemiology and genetic diversity of colistin nonsusceptible nosocomial Acinetobacter baumannii strains from Russia for 2013-2014. Can J Infect Dis Med Microbiol. 2017;1839190:1–5.
   Google Scholar
• Carrasco L, Dabul ANG, Boralli C, et al. Polymyxin resistance among XDR ST1 carbapenem-resistant Acinetobacter baumannii clone expanding in a teaching hospital. Front Microbiol. 2021;12:622704.
   PubMedGoogle Scholar
• Sherry N, Howden B. Emerging Gram negative resistance to last-line antimicrobial agents fosfomycin, colistin and ceftazidime-avibactam–epidemiology, laboratory detection and treatment implications. Expert Rev Anti Infect Ther. 2018;16(4):289–306.
   PubMed Web of Science ®Google Scholar
• European Centre for Disease Prevention and Control. Surveillance of antimicrobial resistance in Europe–annual report of the European antimicrobial resistance surveillance network (EARS-Net) 2017. Stockholm: ECDC; 2018. [cited 2020 Sep 20]. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/AMR%202017_Cover%2BInner-web_v3.pdf
   Google Scholar
• Acar A, Karaahmetoğlu G, Akalın H, et al. Pooled prevalence and trends of antimicrobial resistance in Pseudomonas aeruginosa clinical isolates over the past 10 years in Turkey: a meta-analysis. J Glob Antimicrob Resist. 2019;18:64–70.
   PubMed Web of Science ®Google Scholar
• Apisarnthanarak A, Hsu LY, Khawcharoenporn T, et al. Carbapenem-resistant Gram-negative bacteria: how to prioritize infection prevention and control interventions in resource-limited settings? Expert Rev Anti Infect Ther. 2013;11(2):147–157.
   PubMed Web of Science ®Google Scholar
• Goli HR, Nahaei MR, Rezaee MA, et al. Emergence of colistin resistant Pseudomonas aeruginosa at Tabriz hospitals, Iran. Iran J Microbiol. 2016;8(1):62.
   PubMedGoogle Scholar
• Dogonchi AA, Ghaemi EA, Ardebili A, et al. Metallo-β-lactamase-mediated resistance among clinical carbapenem-resistant Pseudomonas aeruginosa isolates in northern Iran: a potential threat to clinical therapeutics. Tzu Chi Med J. 2018;30(2):90.
   Google Scholar
• Shahri FN, Izanloo A, Sheikh Beig Goharrizi MA, et al. Antimicrobial resistance, virulence factors, and genotypes of Pseudomonas aeruginosa clinical isolates from Gorgan, northern Iran. Int Microbiol. 2022;25(4):709–721.
   PubMedGoogle Scholar
• Bakht M, Alizadeh SA, Rahimi S, et al. Phenotype and genetic determination of resistance to common disinfectants among biofilm-producing and non-producing Pseudomonas aeruginosa strains from clinical specimens in Iran. BMC Microbiol. 2022;22(1):1–16.
   PubMedGoogle Scholar
• Rad ZR, Rad ZR, Goudarzi H, et al. Detection of New Delhi Metallo-β-lactamase-1 among Pseudomonas aeruginosa isolated from adult and pediatric patients in Iranian hospitals. Gene Rep. 2021;23:101152.
   Web of Science ®Google Scholar
• Humphries RM. Susceptibility testing of the polymyxins: where are we now? Pharmacotherapy. 2015;35(1):22–27.
   PubMed Web of Science ®Google Scholar
• European Committee on Antimicrobial Susceptibility Testing (EUCAST). Recommendations for MIC determination of colistin (polymyxin E) as recommended by the joint CLSI-EUCAST Polymyxin Breakpoints Working Group. Växjö: EUCAST; 2016. [cited 2018 Aug 12]. Available from: http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/General_documents/Recommendations_for_MIC_determination_of_colistin_March_2016.pdf
   Google Scholar
• Dafopoulou K, Zarkotou O, Dimitroulia E, et al. Comparative evaluation of colistin susceptibility testing methods among carbapenem-nonsusceptible Klebsiella pneumoniae and Acinetobacter baumannii clinical isolates. Antimicrob Agents Chemother. 2015;59(8):4625–4630.
   PubMed Web of Science ®Google Scholar
• Matuschek E, Åhman J, Webster C, et al. Antimicrobial susceptibility testing of colistin–evaluation of seven commercial MIC products against standard broth microdilution for Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter spp. Clin Microbiol Infect. 2018;24(8):865–870.
   PubMed Web of Science ®Google Scholar
• Tan T, Ng S. Comparison of Etest, Vitek and agar dilution for susceptibility testing of colistin. Clin Microbiol Infect. 2007;13(5):541–544.
   PubMed Web of Science ®Google Scholar
• Vourli S, Dafopoulou K, Vrioni G, et al. Evaluation of two automated systems for colistin susceptibility testing of carbapenem-resistant Acinetobacter baumannii clinical isolates. J Antimicrob Chemother. 2017;72(9):2528–2530.
   PubMed Web of Science ®Google Scholar
• Albur M, Noel A, Bowker K, et al. Colistin susceptibility testing: time for a review. J Antimicrob Chemother. 2014;69(5):1432–1434.
   PubMed Web of Science ®Google Scholar
• Karvanen MC, Mohamad A, Lagerback P. Colistin is extensively lost during normal experimental conditions. Abstr D-690, p 160. Abstr 51st Intersci Conf Antimicrob Agents Chemother. 2011. American Society for Microbiology, Washington, DC.
   Google Scholar
• Hawley JS, Murray CK, Griffith ME, et al. Susceptibility of Acinetobacter strains isolated from deployed US military personnel. Antimicrob Agents Chemother. 2007;51(1):376–378.
   PubMed Web of Science ®Google Scholar
• Schurek KN, Sampaio JL, Kiffer CR, et al. Involvement of pmrAB and phoPQ in polymyxin B adaptation and inducible resistance in non-cystic fibrosis clinical isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2009;53(10):4345–4351.
   PubMed Web of Science ®Google Scholar
• Li J, Nation RL, Turnidge JD, et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis. 2006;6(9):589–601.
   PubMed Web of Science ®Google Scholar
• Landman D, Georgescu C, Martin DA, et al. Polymyxins revisited. Clin Microbiol Rev. 2008;21(3):449–465.
   PubMed Web of Science ®Google Scholar
• Li J, Milne RW, Nation RL, et al. Stability of colistin and colistin methanesulfonate in aqueous media and plasma as determined by high-performance liquid chromatography. Antimicrob Agents Chemother. 2003;47(4):1364–1370.
   PubMed Web of Science ®Google Scholar
• Gupta S, Govil D, Kakar PN, et al. Colistin and polymyxin B: a re-emergence. Indian J Crit Care Med. 2009;13(2):49.
   PubMedGoogle Scholar
• Chen LF, Kaye D. Current use for old antibacterial agents: polymyxins, rifamycins, and aminoglycosides. Infect Dis Clin North Am. 2009;23(4):1053–1075.
   PubMed Web of Science ®Google Scholar
• Barnett M, Bushby SM, Wilkinson S. Sodium sulphomethyl derivatives of polymyxins. Br J Pharmacol. 1964;23(3):552–574.
   PubMed Web of Science ®Google Scholar
• Bergen PJ, Li J, Rayner CR, et al. Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2006;50(6):1953–1958.
   PubMed Web of Science ®Google Scholar
• Cheah S-E, Wang J, Nguyen VTT, et al. New pharmacokinetic/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: smaller response in lung infection. J Antimicrob Chemother. 2015;70(12):3291–3297.
   PubMed Web of Science ®Google Scholar
• Sorlí L, Luque S, Grau S, et al. Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study. BMC Infect Dis. 2013;13(1):1–9.
   PubMedGoogle Scholar
• Forrest A, Silveira F, Thamlikitkul V, et al. Toxicodynamics for colistin-associated changes in creatinine clearance. Abstr A-038a. Abstr 54th Intersci Conf Antimicrob Agents Chemother. 2014. American Society for Microbiology, Washington, DC.
   Google Scholar
• Rattanaumpawan P, Ungprasert P, Thamlikitkul V. Risk factors for colistin-associated nephrotoxicity. J Infect. 2011;62(2):187–190.
   PubMed Web of Science ®Google Scholar
• Nation RL, Velkov T, Li J. Colistin and polymyxin B: peas in a pod, or chalk and cheese? Clin Infect Dis. 2014;59(1):88–94.
   PubMed Web of Science ®Google Scholar
• Nation RL, Li J. Optimizing use of colistin and polymyxin B in the critically ill. Semin Respir Crit Care Med. 2007;28:604–614.
   PubMedGoogle Scholar
• Landersdorfer CB, Nation RL. Colistin: how should it be dosed for the critically ill? Semin Respir Crit Care Med. 2015;36(1):126–135.
   PubMed Web of Science ®Google Scholar
• Ma Z, Wang J, Nation RL, et al. Renal disposition of colistin in the isolated perfused rat kidney. Antimicrob Agents Chemother. 2009;53(7):2857–2864.
   PubMedGoogle Scholar
• Couet W, Gregoire N, Marchand S, et al. Colistin pharmacokinetics: the fog is lifting. Clin Microbiol Infect. 2012;18(1):30–39.
   PubMed Web of Science ®Google Scholar
• Imberti R, Cusato M, Villani P, et al. Steady-state pharmacokinetics and BAL concentration of colistin in critically Ill patients after IV colistin methanesulfonate administration. Chest. 2010;138(6):1333–1339.
   PubMed Web of Science ®Google Scholar
• Plachouras D, Karvanen M, Friberg L, et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by Gram-negative bacteria. Antimicrob Agents Chemother. 2009;53(8):3430–3436.
   PubMed Web of Science ®Google Scholar
• Mohamed AF, Karaiskos I, Plachouras D, et al. Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill. Clin Microbiol Infect. 2012;56(8):4241–4249.
   Google Scholar
• Karaiskos I, Friberg LE, Pontikis K, et al. Colistin population pharmacokinetics after application of a loading dose of 9 MU colistin methanesulfonate in critically ill patients. Clin Microbiol Infect. 2015;59(12):7240–7248.
   Google Scholar
• Dalfino L, Puntillo F, Mosca A, et al. High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study. Clin Infect Dis. 2012;54(12):1720–1726.
   PubMed Web of Science ®Google Scholar
• Markou N, Markantonis SL, Dimitrakis E, et al. Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, Gram-negative bacilli infections: a prospective, open-label, uncontrolled study. Clin Ther. 2008;30(1):143–151.
   PubMed Web of Science ®Google Scholar
• Garonzik S, Li J, Thamlikitkul V, et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother. 2011;55(7):3284–3294.
   PubMed Web of Science ®Google Scholar
• Reed MD, Stern RC, O’Riordan MA, et al. The pharmacokinetics of colistin in patients with cystic fibrosis. J Clin Pharmacol. 2001;41(6):645–654.
   PubMed Web of Science ®Google Scholar
• Li J, Coulthard K, Milne R, et al. Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis. J Antimicrob Chemother. 2003;52(6):987–992.
   PubMed Web of Science ®Google Scholar
• Littlewood JM, Koch C, Lambert PA, et al. A ten year review of colomycin. Respir Med. 2000;94(7):632–640.
   PubMed Web of Science ®Google Scholar
• Jensen T, Pedersen SS, Garne S, et al. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J Antimicrob Chemother. 1987;19(6):831–838.
   PubMed Web of Science ®Google Scholar
• Yapa SWS, Li J, Patel K, et al. Pulmonary and systemic pharmacokinetics of inhaled and intravenous colistin methanesulfonate in cystic fibrosis patients: targeting advantage of inhalational administration. Antimicrob Agents Chemother. 2014;58(5):2570–2579.
   PubMed Web of Science ®Google Scholar
• Kaplan S, Lee A, Caine N, et al. Long-term safety study of colistimethate sodium (Colobreathe®): findings from the UK Cystic Fibrosis Registry. J Cyst Fibros. 2021;20(2):324–329.
   PubMedGoogle Scholar
• Markantonis S, Markou N, Fousteri M, et al. Penetration of colistin into cerebrospinal fluid. Antimicrob Agents Chemother. 2009;53(11):4907–4910.
   PubMed Web of Science ®Google Scholar
• Imberti R, Cusato M, Accetta G, et al. Pharmacokinetics of colistin in cerebrospinal fluid after intraventricular administration of colistin methanesulfonate. Antimicrob Agents Chemother. 2012;56(8):4416–4421.
   PubMed Web of Science ®Google Scholar
• Phe K, Lee Y, McDaneld PM, et al. In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy. Antimicrob Agents Chemother. 2014;58(5):2740–2746.
   PubMed Web of Science ®Google Scholar
• Zavascki AP, Nation RL. Nephrotoxicity of Polymyxins: is There Any Difference between Colistimethate and Polymyxin B? Antimicrob Agents Chemother. 2017;61(3):1–10.
   Web of Science ®Google Scholar
• Rigatto MH, Oliveira MS, Perdigão-Neto LV, et al. Multicenter prospective cohort study of renal failure in patients treated with colistin versus polymyxin B. Antimicrob Agents Chemother. 2016;60(4):2443–2449.
   PubMed Web of Science ®Google Scholar
• Tsuji BT, Pogue JM, Zavascki AP, et al. International consensus guidelines for the optimal use of the polymyxins: endorsed by the American college of clinical pharmacy (ACCP), European society of clinical microbiology and infectious diseases (ESCMID), infectious diseases society of America (IDSA), international society for anti‐infective pharmacology (ISAP), society of critical care medicine (SCCM), and society of infectious diseases pharmacists (SIDP). Pharmacotherapy. 2019;39(1):10–39.
   PubMed Web of Science ®Google Scholar
• Bian X, Liu X, Hu F, et al. Pharmacokinetic/pharmacodynamic based breakpoints of polymyxin B for bloodstream infections caused by multidrug-resistant Gram-negative pathogens. Front Pharmacol. 2021;12:1–8.
   Google Scholar
• Zavascki AP, Goldani LZ, Cao G, et al. Pharmacokinetics of intravenous polymyxin B in critically ill patients. Clin Infect Dis. 2008;47(10):1298–1304.
   PubMed Web of Science ®Google Scholar
• Sandri AM, Landersdorfer CB, Jacob J, et al. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. Clin Infect Dis. 2013;57(4):524–531.
   PubMed Web of Science ®Google Scholar
• Li Y, Deng Y, Zhu Z-Y, et al. Population pharmacokinetics of polymyxin B and dosage optimization in renal transplant patients. Front Pharmacol. 2021;12:1–9.
   Web of Science ®Google Scholar
• Manchandani P, Thamlikitkul V, Dubrovskaya Y, et al. Population pharmacokinetics of polymyxin B. Clin Pharmacol Ther. 2018;104(3):534–538.
   PubMedGoogle Scholar
• Kubin CJ, Nelson BC, Miglis C, et al. Population pharmacokinetics of intravenous polymyxin B from clinical samples. Antimicrob Agents Chemother. 2018;62(3):e01493–17.
   PubMedGoogle Scholar
• Lakota EA, Landersdorfer CB, Nation RL, et al. Personalizing polymyxin B dosing using an adaptive feedback control algorithm. Antimicrob Agents Chemother. 2018;62(7):1–9.
   Google Scholar
• Miglis C, Rhodes NJ, Avedissian SN, et al. Population Pharmacokinetics of Polymyxin B in Acutely Ill Adult Patients. Antimicrob Agents Chemother. 2018;62(3):1–12.
   Google Scholar
• Kollef MH. Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. Clin Infect Dis. 2000;31(Supplement_4):S131–S8.
   PubMedGoogle Scholar
• Bhat S, Fujitani S, Potoski BA, et al. Pseudomonas aeruginosa infections in the intensive care unit: can the adequacy of empirical β-lactam antibiotic therapy be improved? Int J Antimicrob Agents. 2007;30(5):458–462.
   PubMedGoogle Scholar
• Geerdes HF, Ziegler D, Lode H, et al. Septicemia in 980 patients at a university hospital in Berlin: prospective studies during 4 selected years between 1979 and 1989. Clin Infect Dis. 1992;15(6):991–1002.
   PubMedGoogle Scholar
• Daikos GL, Tsaousi S, Tzouvelekis LS, et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother. 2014;58(4):2322–2328.
   PubMed Web of Science ®Google Scholar
• Falagas ME, Kasiakou SK, Saravolatz LD. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis. 2005;40(9):1333–1341.
   PubMed Web of Science ®Google Scholar
• Landersdorfer CB, Ly NS, Xu H. Quantifying subpopulation synergy for antibiotic combinations via mechanism-based modeling and a sequential dosing design. Antimicrob Agents Chemother. 2013;57(5):2343–2351.
   PubMed Web of Science ®Google Scholar
• Sharma R, Patel S, Abboud C, et al. Polymyxin B in combination with meropenem against carbapenemase-producing Klebsiella pneumoniae: pharmacodynamics and morphological changes. Int J Antimicrob Agents. 2017;49(2):224–232.
   PubMedGoogle Scholar
• Ferrer-Espada R, Shahrour H, Pitts B, et al. A permeability-increasing drug synergizes with bacterial efflux pump inhibitors and restores susceptibility to antibiotics in multi-drug resistant Pseudomonas aeruginosa strains. Sci Rep. 2019;9(1):1–12.
   PubMedGoogle Scholar
• Bolla J-M, Alibert-Franco S, Handzlik J, et al. Strategies for bypassing the membrane barrier in multidrug resistant Gram-negative bacteria. FEBS Lett. 2011;585(11):1682–1690.
   PubMed Web of Science ®Google Scholar
• Zampieri M, Zimmermann M, Claassen M, et al. Nontargeted metabolomics reveals the multilevel response to antibiotic perturbations. Cell Rep. 2017;19(6):1214–1228.
   PubMedGoogle Scholar
• Vincent IM, Ehmann DE, Mills SD, et al. Untargeted metabolomics to ascertain antibiotic modes of action. Antimicrob Agents Chemother. 2016;60(4):2281–2291.
   PubMed Web of Science ®Google Scholar
• Jia J, Zhu F, Ma X, et al. Mechanisms of drug combinations: interaction and network perspectives. Nat Rev Drug Discov. 2009;8(2):111–128.
   PubMed Web of Science ®Google Scholar
• Chen C, Gonzalez FJ, Idle JR. LC-MS-based metabolomics in drug metabolism. Drug Metab Rev. 2007;39(2–3):581–597.
   PubMed Web of Science ®Google Scholar
• Han M-L, Liu X, Velkov T, et al. Metabolic analyses revealed time-dependent synergistic killing by colistin and aztreonam combination against multidrug-resistant Acinetobacter baumannii. Front Microbiol. 2018;9:2776.
   PubMedGoogle Scholar
• Maifiah MHM, Creek DJ, Nation RL, et al. Untargeted metabolomics analysis reveals key pathways responsible for the synergistic killing of colistin and doripenem combination against Acinetobacter baumannii. Sci Rep. 2017;7:45527.
   PubMed Web of Science ®Google Scholar
• Hussein M, Han M-L, Zhu Y, et al. Metabolomics study of the synergistic killing of polymyxin B in combination with amikacin against polymyxin-susceptible and-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2019;64(1):1–16.
   Google Scholar
• Han M-L, Liu X, Velkov T, et al. Comparative metabolomics reveals key pathways associated with the synergistic killing of colistin and sulbactam combination against multidrug-resistant Acinetobacter baumannii. Front Pharmacol. 2019;10:754.
   PubMedGoogle Scholar
• Bian X, Liu X, Chen Y, et al. Dose optimization of colistin combinations against carbapenem-resistant Acinetobacter baumannii from patients with hospital-acquired pneumonia in China by using an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother. 2019;63(4):1–12.
   Google Scholar
• Cai B, Cai Y, Liew YX, et al. Clinical efficacy of polymyxin monotherapy versus nonvalidated polymyxin combination therapy versus validated polymyxin combination therapy in extensively drug-resistant Gram-negative Bacillus infections. Antimicrob Agents Chemother. 2016;60(7):4013–4022.
   PubMedGoogle Scholar
• Zusman O, Avni T, Leibovici L, et al. Systematic review and meta-analysis of in vitro synergy of polymyxins and carbapenems. Antimicrob Agents Chemother. 2013;57(10):5104–5111.
   PubMed Web of Science ®Google Scholar
• Bergen PJ, Bulman ZP, Saju S, et al. Polymyxin combinations: pharmacokinetics and pharmacodynamics for rationale use. Pharmacotherapy. 2015;35(1):34–42.
   PubMedGoogle Scholar
• Manian FA, Meyer L, Jenne J, et al. Loss of antimicrobial susceptibility in aerobic Gram-negative bacilli repeatedly isolated from patients in intensive-care units. Infect Control Hosp Epidemiol. 1996;17(4):222–226.
   PubMedGoogle Scholar
• Ni W, Cai X, Wei C, et al. Efficacy of polymyxins in the treatment of carbapenem-resistant Enterobacteriaceae infections: a systematic review and meta-analysis. Braz J Infect Dis. 2015;19:170–180.
   PubMed Web of Science ®Google Scholar
• Durante-Mangoni E, Signoriello G, Andini R, et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis. 2013;57(3):349–358.
   PubMed Web of Science ®Google Scholar
• Tängdén T. Combination antibiotic therapy for multidrug-resistant Gram-negative bacteria. Ups J Med Sci. 2014;119(2):149–153.
   PubMed Web of Science ®Google Scholar
• Hariton E, Locascio JJ. Randomised controlled trials—The gold standard for effectiveness research. Int J Obstet Gynaecol. 2018;125(13):1716.
   Google Scholar
• Paul M, Carmeli Y, Durante-Mangoni E, et al. Combination therapy for carbapenem-resistant Gram-negative bacteria. J Antimicrob Chemother. 2014;69(9):2305–2309.
   PubMed Web of Science ®Google Scholar
• Zusman O, Altunin S, Koppel F, et al. Polymyxin monotherapy or in combination against carbapenem-resistant bacteria: systematic review and meta-analysis. J Antimicrob Chemother. 2016;72(1):29–39.
   PubMedGoogle Scholar
• Tumbarello M, Viale P, Viscoli C, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase–producing K. pneumoniae: importance of combination therapy. Clin Infect Dis. 2012;55(7):943–950.
   PubMed Web of Science ®Google Scholar
• Paul M, Kariv G, Goldberg E, et al. Importance of appropriate empirical antibiotic therapy for methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother. 2010;65(12):2658–2665.
   PubMed Web of Science ®Google Scholar
• Sirijatuphat R, Thamlikitkul V. Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections. Antimicrob Agents Chemother. 2014;58(9):5598–5601.
   PubMed Web of Science ®Google Scholar
• Aydemir H, Akduman D, Piskin N, et al. Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia. Epidemiol Infect. 2013;141(6):1214–1222.
   PubMed Web of Science ®Google Scholar
• Qureshi ZA, Paterson DL, Potoski BA, et al. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother. 2012;56(4):2108–2113.
   PubMed Web of Science ®Google Scholar
• Li J, Nation RL, Owen RJ, et al. Antibiograms of multidrug-resistant clinical Acinetobacter baumannii: promising therapeutic options for treatment of infection with colistin-resistant strains. Clin Infect Dis. 2007;45(5):594–598.
   PubMedGoogle Scholar
• Tripodi M-F, Durante-Mangoni E, Fortunato R, et al. Comparative activities of colistin, rifampicin, imipenem and sulbactam/ampicillin alone or in combination against epidemic multidrug-resistant Acinetobacter baumannii isolates producing OXA-58 carbapenemases. Int J Antimicrob Agents. 2007;30(6):537–540.
   PubMed Web of Science ®Google Scholar
• Lee HJ, Bergen PJ, Bulitta JB, et al. Synergistic activity of colistin and rifampin combination against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother. 2013;57(8):3738–3745.
   PubMed Web of Science ®Google Scholar
• Pantopoulou A, Giamarellos-Bourboulis EJ, Raftogannis M, et al. Colistin offers prolonged survival in experimental infection by multidrug-resistant Acinetobacter baumannii: the significance of co-administration of rifampicin. Int J Antimicrob Agents. 2007;29(1):51–55.
   PubMedGoogle Scholar
• Pachón-Ibáñez ME, Labrador-Herrera G, Cebrero-Cangueiro T, et al. Efficacy of colistin and its combination with rifampin in vitro and in experimental models of infection caused by carbapenemase-producing clinical isolates of Klebsiella pneumoniae. Front Microbiol. 2018;9:912.
   PubMed Web of Science ®Google Scholar
• Batirel A, Balkan I, Karabay O, et al. Comparison of colistin–carbapenem, colistin–sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections. Eur J Clin Microbiol Infect Dis. 2014;33(8):1311–1322.
   PubMed Web of Science ®Google Scholar
• Simsek F, Gedik H, Yildirmak M, et al. Colistin against colistin-only-susceptible Acinetobacter baumannii-related infections: monotherapy or combination therapy? Indian J Med Microbiol. 2012;30(4):448.
   PubMed Web of Science ®Google Scholar
• Pournaras S, Vrioni G, Neou E, et al. Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay. Int J Antimicrob Agents. 2011;37(3):244–247.
   PubMed Web of Science ®Google Scholar
• Clancy CJ, Chen L, Hong JH, et al. Mutations of the ompK36 porin gene and promoter impact responses of sequence type 258, KPC-2-producing Klebsiella pneumoniae strains to doripenem and doripenem-colistin. Antimicrob Agents Chemother. 2013;57(11):5258–5265.
   PubMedGoogle Scholar
• Fadare FT, Elsheikh EAE, Okoh AI. In vitro assessment of the combination of antibiotics against some integron-harbouring Enterobacteriaceae from environmental sources. Antibiotics (Basel). 2022;11(8):1–13.
   Google Scholar
• Deris ZZ, Yu HH, Davis K, et al. The combination of colistin and doripenem is synergistic against Klebsiella pneumoniae at multiple inocula and suppresses colistin resistance in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother. 2012;56(10):5103–5112.
   PubMed Web of Science ®Google Scholar
• Teo JQ, Fauzi N, Ho JJ, et al. In vitro bactericidal activities of combination antibiotic therapies against carbapenem-resistant Klebsiella pneumoniae with different carbapenemases and sequence types. Front Microbiol. 2021;12:779988.
   PubMedGoogle Scholar
• Lim TP, Cai Y, Hong Y, et al. In vitro pharmacodynamics of various antibiotics in combination against extensively drug-resistant Klebsiella pneumoniae. Antimicrob Agents Chemother. 2015;59(5):2515–2524.
   PubMed Web of Science ®Google Scholar
• Jernigan MG, Press EG, Nguyen MH. The combination of doripenem and colistin is bactericidal and synergistic against colistin-resistant, carbapenemase-producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2012;56(6):3395–3398.
   PubMed Web of Science ®Google Scholar
• Demiraslan H, Dinc G, Ahmed SS, et al. Carbapenem-resistant Klebsiella pneumoniae sepsis in corticosteroid receipt mice: tigecycline or colistin monotherapy versus tigecycline/colistin combination. J Chemother. 2014;26(5):276–281.
   PubMed Web of Science ®Google Scholar
• Michail G, Labrou M, Pitiriga V, et al. Activity of tigecycline in combination with colistin, meropenem, rifampin, or gentamicin against KPC-producing Enterobacteriaceae in a murine thigh infection model. Antimicrob Agents Chemother. 2013;57(12):6028–6033.
   PubMed Web of Science ®Google Scholar
• Gaibani P, Lombardo D, Lewis RE, et al. In vitro activity and post-antibiotic effects of colistin in combination with other antimicrobials against colistin-resistant KPC-producing Klebsiella pneumoniae bloodstream isolates. J Antimicrob Chemother. 2014;69(7):1856–1865.
   PubMed Web of Science ®Google Scholar
• Drawz SM, Bonomo RA. Three decades of β-lactamase inhibitors. Clin Microbiol Rev. 2010;23(1):160–201.
   PubMed Web of Science ®Google Scholar
• Wong D, Van Duin D. Novel beta-lactamase inhibitors: unlocking their potential in therapy. Drugs. 2017;77(6):615–628.
   PubMed Web of Science ®Google Scholar
• van Duin D, Bonomo RA. Ceftazidime/avibactam and ceftolozane/tazobactam: second-generation β-lactam/β-lactamase inhibitor combinations. Clin Infec Dis. 2016;63(2):234–241.
   PubMed Web of Science ®Google Scholar
• de Jonge BL, Karlowsky JA, Kazmierczak KM, et al. In vitro susceptibility to ceftazidime-avibactam of carbapenem-nonsusceptible Enterobacteriaceae isolates collected during the INFORM global surveillance study (2012 to 2014). Antimicrob Agents Chemother. 2016;60(5):3163–3169.
   PubMed Web of Science ®Google Scholar
• Spiliopoulou I, Kazmierczak K, Stone GG. In vitro activity of ceftazidime/avibactam against isolates of carbapenem-non-susceptible Enterobacteriaceae collected during the INFORM global surveillance programme (2015–17). J Antimicrob Chemother. 2019;75(2):384–931.
   Google Scholar
• Karlowsky JA, Kazmierczak KM, Bouchillon SK. In vitro activity of ceftazidime-avibactam against clinical isolates of Enterobacteriaceae and Pseudomonas aeruginosa collected in Asia-Pacific countries: results from the INFORM global surveillance program, 2012 to 2015. Antimicrob Agents Chemother. 2018;62(7):e02569–17.
   PubMedGoogle Scholar
• Shields RK, Nguyen MH, Chen L, et al. Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia. Antimicrob Agents Chemother. 2017;61(8):e00883–17.
   PubMed Web of Science ®Google Scholar
• Van Duin D, Lok JJ, Earley M, et al. Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae. Clin Infect Dis. 2018;66(2):163–171.
   PubMed Web of Science ®Google Scholar
• Lee Y, Kim J, Trinh S. Meropenem–vaborbactam (Vabomere™): another option for carbapenem-resistant Enterobacteriaceae. Pharmacol Ther. 2019;44(3):110.
   Google Scholar
• Hecker SJ, Reddy KR, Totrov M, et al. Discovery of a cyclic boronic acid β-lactamase inhibitor (RPX7009) with utility vs class A serine carbapenemases. J Med Chem. 2015 14;58(9):3682–3692.
   PubMed Web of Science ®Google Scholar
• Castanheira M, Huband MD, Mendes RE, et al. Meropenem-vaborbactam tested against contemporary Gram-negative isolates collected worldwide during 2014, including carbapenem-resistant, KPC-producing, multidrug-resistant, and extensively drug-resistant Enterobacteriaceae. Antimicrob Agents Chemother. 2017;61(9):e00567–17.
   PubMed Web of Science ®Google Scholar
• Wunderink RG, Giamarellos-Bourboulis EJ, Rahav G, et al. Effect and safety of meropenem–vaborbactam versus best-available therapy in patients with carbapenem-resistant enterobacteriaceae infections: the TANGO II randomized clinical trial. Infect Dis Ther. 2018;7(4):439–355.
   PubMed Web of Science ®Google Scholar
• Smith JR, Rybak JM, Claeys KC. Imipenem‐cilastatin‐relebactam: a novel β‐lactam–β‐lactamase Inhibitor combination for the treatment of multidrug‐resistant Gram‐negative infections. Pharmacotherapy. 2020;40(4):343–356.
   PubMed Web of Science ®Google Scholar
• Livermore DM, Warner M, Mushtaq S. Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa. J Antimicrob Chemother. 2013;68(10):2286–2290.
   PubMed Web of Science ®Google Scholar
• Karaiskos I, Galani I, Papoutsaki V, et al. Carbapenemase producing Klebsiella pneumoniae: implication on future therapeutic strategies. Expert Rev Anti Infect Ther. 2022;20(1):53–69.
   PubMed Web of Science ®Google Scholar
• Motsch J, Murta de Oliveira C, Stus V, et al. RESTORE-IMI 1: a multicenter, randomized, double-blind trial comparing efficacy and safety of imipenem/relebactam vs colistin plus imipenem in patients with imipenem-nonsusceptible bacterial infections. Clin Infect Dis. 2020;70(9):1799–1808.
   PubMed Web of Science ®Google Scholar
• Wright H, Bonomo RA, Paterson DL, et al. New agents for the treatment of infections with Gram-negative bacteria: restoring the miracle or false Dawn? Clin Microbiol Infect. 2017;23(10):704–712.
   PubMed Web of Science ®Google Scholar
• Shields RK, Potoski BA, Haidar G, et al. Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections. Clin Infect Dis. 2016;63(12):1615–1618.
   PubMed Web of Science ®Google Scholar
• Barnes MD, Winkler ML, Taracila MA, et al. Klebsiella pneumoniae carbapenemase-2 (KPC-2), substitutions at Ambler position Asp179, and resistance to ceftazidime-avibactam: unique antibiotic-resistant phenotypes emerge from β-lactamase protein engineering. mBio. 2017;8(5):e00528–17.
   PubMed Web of Science ®Google Scholar
• Crusio R, Rao S, Changawala N, et al. Epidemiology and outcome of infections with carbapenem-resistant Gram-negative bacteria treated with polymyxin B-based combination therapy. Scand J Infect Dis. 2014;46(1):1–8.
   PubMed Web of Science ®Google Scholar
• Michalopoulos A, Virtzili S, Rafailidis P, et al. Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation. Clin Microbiol Infect. 2010;16(2):184–186.
   PubMed Web of Science ®Google Scholar
• Zarkotou O, Pournaras S, Tselioti P, et al. Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment. Clin Microbiol Infect. 2011;17(12):1798–1803.
   PubMed Web of Science ®Google Scholar
• Bergamasco M, Barroso Barbosa M, de Oliveira Garcia D, et al. Infection with Klebsiella pneumoniae carbapenemase (KPC)‐producing K. pneumoniae in solid organ transplantation Transpl Infect Dis. 2012;14(2):198–205.
   PubMed Web of Science ®Google Scholar
• Abdelsalam MFA, Abdalla MS, El-Abhar HSE-D. Prospective, comparative clinical study between high-dose colistin monotherapy and colistin–meropenem combination therapy for treatment of hospital-acquired pneumonia and ventilator-associated pneumonia caused by multidrug-resistant Klebsiella pneumoniae. J of Global Antimicrobial Resistance. 2018;15:127–135.
   PubMed Web of Science ®Google Scholar
• Oliva A, Scorzolini L, Castaldi D, et al. Double-carbapenem regimen, alone or in combination with colistin, in the treatment of infections caused by carbapenem-resistant Klebsiella pneumoniae (CR-Kp). J Infect. 2017;74(1):103–106.
   PubMed Web of Science ®Google Scholar
• Balkan II, Aygün G, Aydın S, et al. Blood stream infections due to OXA-48-like carbapenemase-producing Enterobacteriaceae: treatment and survival. Int J Infect Dis. 2014;26:51–56.
   PubMed Web of Science ®Google Scholar
• Tascini C, Gemignani G, Palumbo F, et al. Clinical and microbiological efficacy of colistin therapy alone or in combination as treatment for multidrug resistant Pseudomonas aeruginosa diabetic foot infections with or without osteomyelitis. J Chemother. 2006;18(6):648–651.
   PubMed Web of Science ®Google Scholar
• Falagas M, Rafailidis P, Kasiakou S, et al. Effectiveness and nephrotoxicity of colistin monotherapy vs. colistin–meropenem combination therapy for multidrug-resistant Gram-negative bacterial infections. Clin Microbiol Infect. 2006;12(12):1227–1230.
   PubMed Web of Science ®Google Scholar
• Pintado V, San Miguel LG, Grill F, et al. Intravenous colistin sulphomethate sodium for therapy of infections due to multidrug-resistant Gram-negative bacteria. J Infect. 2008;56(3):185–190.
   PubMed Web of Science ®Google Scholar
• Souli M, Kontopidou FV, Papadomichelakis E, et al. Clinical experience of serious infections caused by Enterobacteriaceae producing VIM-1 metallo-β-lactamase in a Greek university hospital. ClinInfect Dis. 2008;46(6):847–854.
   PubMedGoogle Scholar
• Jang HJ, Kim M-N, Lee K, et al. The comparative efficacy of colistin monotherapy and combination therapy based on in vitro antimicrobial synergy in ventilator-associated pneumonia caused by multi-drug resistant Acinetobacter baumannii. Tuberc Respir Dis. 2009;67(3):212–220.
   Google Scholar
• Falagas ME, Rafailidis PI, Ioannidou E, et al. Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients. Int J Antimicrob Agents. 2010;35(2):194–199.
   PubMed Web of Science ®Google Scholar
• Mouloudi E, Protonotariou E, Zagorianou A, et al. Bloodstream infections caused by metallo-β-lactamase/Klebsiella pneumoniae carbapenemase–producing K. pneumoniae among intensive care unit patients in Greece: risk factors for infection and impact of type of resistance on outcomes. Infect Control Hosp Epidemiol. 2010;31(12):1250–1256.
   PubMed Web of Science ®Google Scholar
• Hernández-Torres A, García-Vázquez E, Gómez J, et al. Multidrug and carbapenem-resistant Acinetobacter baumannii infections: factors associated with mortality. Med Clin. 2012;138(15):650–655.
   PubMed Web of Science ®Google Scholar
• Şimşek F, Gedik H, Yıldırmak M, et al. Colistin against colistin-only-susceptible Acinetobacter baumannii-related infections: monotherapy or combination therapy? Indian J Med Microbiol. 2012;30(4):448–452.
   PubMed Web of Science ®Google Scholar
• Ku K, Pogue JM, Moshos J, et al. Retrospective evaluation of colistin versus tigecycline for the treatment of Acinetobacter baumannii and/or carbapenem-resistant Enterobacteriaceae infections. Am J Infect Control. 2012;40(10):983–987.
   PubMedGoogle Scholar
• Navarro‐San Francisco C, Mora‐Rillo M, Romero‐Gómez M, et al. Bacteraemia due to OXA‐48‐carbapenemase‐producing Enterobacteriaceae: a major clinical challenge. Clin Microbiol Infect. 2013;19(2):E72–E9.
   PubMed Web of Science ®Google Scholar
• Capone A, Giannella M, Fortini D, et al. High rate of colistin resistance among patients with carbapenem-resistant Klebsiella pneumoniae infection accounts for an excess of mortality. Clin Microbiol Infect. 2013;19(1):E23–E30.
   PubMed Web of Science ®Google Scholar
• Garnacho-Montero J, Amaya-Villar R, Gutiérrez-Pizarraya A, et al. Clinical efficacy and safety of the combination of colistin plus vancomycin for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii. Chemotherapy. 2013;59(3):225–231.
   PubMed Web of Science ®Google Scholar
• Kalin G, Alp E, Akin A, et al. Comparison of colistin and colistin/sulbactam for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia. Infection. 2014;42(1):37–42.
   PubMedGoogle Scholar
• Kontopidou F, Giamarellou H, Katerelos P, et al. Infections caused by carbapenem-resistant Klebsiella pneumoniae among patients in intensive care units in Greece: a multi-centre study on clinical outcome and therapeutic options. Clin Microbiol Infect. 2014;20(2):O117–O23.
   PubMed Web of Science ®Google Scholar
• López-Cortés L, Cisneros J, Fernández-Cuenca F, et al. Monotherapy versus combination therapy for sepsis due to multidrug-resistant Acinetobacter baumannii: analysis of a multicentre prospective cohort. J Antimicrob Chemother. 2014;69(11):3119–3126.
   PubMed Web of Science ®Google Scholar
• Porwal R, Gopalakrishnan R, Rajesh NJ, et al. Carbapenem resistant Gram-negative bacteremia in an Indian intensive care unit: a review of the clinical profile and treatment outcome of 50 patients. Indian J Crit Care Med. 2014;18(11):750.
   PubMedGoogle Scholar
• Parchem N, Bauer K, Cook C, et al. Colistin combination therapy improves microbiologic cure in critically ill patients with multi-drug resistant Gram-negative pneumonia. Eur J Clin Microbiol. 2016;35(9):1433–1439.
   Google Scholar
• Dickstein Y, Lellouche J, Ben Dalak Amar M, et al. Treatment outcomes of colistin-and carbapenem-resistant Acinetobacter baumannii infections: an exploratory subgroup analysis of a randomized clinical trial. Clin Infect Dis. 2019;69(5):769–776.
   PubMed Web of Science ®Google Scholar
• Makris D, Petinaki E, Tsolaki V, et al. Colistin versus colistin combined with ampicillin-sulbactam for multiresistant Acinetobacter baumannii ventilator-associated pneumonia treatment: an open-label prospective study. Indian J Crit Care Med. 2018;22(2):67.
   PubMed Web of Science ®Google Scholar
• Shi H, Lee JS, Park SY, et al. Colistin plus carbapenem versus colistin monotherapy in the treatment of carbapenem-resistant Acinetobacter baumannii pneumonia. Infect Drug Resist. 2019;12:3925.
   PubMed Web of Science ®Google Scholar
• Nutman A, Lellouche J, Temkin E, et al. Colistin plus meropenem for carbapenem-resistant Gram-negative infections: in vitro synergism is not associated with better clinical outcomes. Clin Microbiol Infect. 2020;26(9):1185–1191.
   PubMed Web of Science ®Google Scholar
• Seok H, Choi WS, Lee S, et al. What is the optimal antibiotic treatment strategy for carbapenem-resistant Acinetobacter baumannii (CRAB)? A multicentre study in Korea. J Glob Antimicrob Resist. 2021;24:429–439.
   PubMedGoogle Scholar
• Falagas ME, Lourida P, Poulikakos P, et al. Antibiotic treatment of infections due to carbapenem-resistant Enterobacteriaceae: systematic evaluation of the available evidence. Antimicrob Agents Chemother. 2014;58(2):654–663.
   PubMed Web of Science ®Google Scholar
• Sy CL, Chen P-Y, Cheng C-W, et al. Recommendations and guidelines for the treatment of infections due to multidrug resistant organisms. journal of microbiology, immunology and infection. J Microbiol Immunol Infect. 2022;55(3):359–386.
   PubMedGoogle Scholar
• Herrmann G, Yang L, Wu H, et al. Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa. J Infect Dis. 2010;202(10):1585–1592.
   PubMed Web of Science ®Google Scholar
• Lim TP, Lee W, Tan TY, et al. Effective antibiotics in combination against extreme drug-resistant Pseudomonas aeruginosa with decreased susceptibility to polymyxin B. PLoS One. 2011;6(12):e28177.
   PubMed Web of Science ®Google Scholar
• Walsh CC, Landersdorfer CB, McIntosh MP, et al. Clinically relevant concentrations of fosfomycin combined with polymyxin B, tobramycin or ciprofloxacin enhance bacterial killing of Pseudomonas aeruginosa, but do not suppress the emergence of fosfomycin resistance. J Antimicrob Chemother. 2016;71(8):2218–2229.
   PubMed Web of Science ®Google Scholar
• Ly NS, Bulman ZP, Bulitta JB, et al. Optimization of polymyxin B in combination with doripenem To combat mutator Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2016;60(5):2870–2880.
   PubMedGoogle Scholar
• Armengol E, Asunción T, Viñas M, et al. When combined with colistin, an otherwise ineffective rifampicin–linezolid combination becomes active in Escherichia coli, Pseudomonas aeruginosa, and Acinetobacter baumannii. Microorganisms. 2020;8(1):86.
   PubMedGoogle Scholar
• Lora-Tamayo J, Murillo O, Bergen PJ, et al. Activity of colistin combined with doripenem at clinically relevant concentrations against multidrug-resistant Pseudomonas aeruginosa in an in vitro dynamic biofilm model. J Antimicrob Chemother. 2014;69(9):2434–2442.
   PubMed Web of Science ®Google Scholar
• Ly NS, Bulitta JB, Rao GG, et al. Colistin and doripenem combinations against Pseudomonas aeruginosa: profiling the time course of synergistic killing and prevention of resistance. J Antimicrob Chemother. 2015;70(5):1434–1442.
   PubMed Web of Science ®Google Scholar
• Gunderson BW, Ibrahim KH, Hovde LB, et al. Synergistic activity of colistin and ceftazidime against multiantibiotic-resistant Pseudomonas aeruginosa in an in vitro pharmacodynamic model. Antimicrob Agents Chemother. 2003;47(3):905–909.
   PubMed Web of Science ®Google Scholar
• Caballero VR, Abuhussain SA, Kuti JL, et al. Efficacy of human-simulated exposures of ceftolozane-tazobactam alone and in combination with amikacin or colistin against multidrug-resistant Pseudomonas aeruginosa in an in vitro pharmacodynamic model. Antimicrob Agents Chemother. 2018;62(5):e02384–17.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Vena A, Croxatto A, et al. How to manage Pseudomonas aeruginosa infections. Drugs in Context Drugs Context. 2018;7:1–18.
   Google Scholar
• Escolà-Vergé L, Pigrau C, Almirante B. Ceftolozane/tazobactam for the treatment of complicated intra-abdominal and urinary tract infections: current perspectives and place in therapy. Infect Drug Resist. 2019;12:1853-1867.
   Google Scholar
• Tehrani KH, Martin NI. β-lactam/β-lactamase inhibitor combinations: an update. Medchemcomm. 2018;9(9):1439–1456.
   PubMed Web of Science ®Google Scholar
• Haidar G, Philips NJ, Shields RK, et al. Ceftolozane-tazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa infections: clinical effectiveness and evolution of resistance. Clin Infect Dis. 2017;65(1):110–120.
   PubMed Web of Science ®Google Scholar
• Munita JM, Aitken SL, Miller WR, et al. Multicenter evaluation of ceftolozane/tazobactam for serious infections caused by carbapenem-resistant Pseudomonas aeruginosa. Clin Infect Dis. 2017;65(1):158–161.
   PubMed Web of Science ®Google Scholar
• Yao J, Wang J, Chen M, et al. Cefiderocol: an overview of its in-vitro and in-vivo activity and underlying resistant mechanisms. Front Med (Lausanne). 2021;8(741940):1–7.
   Google Scholar
• Jean -S-S, Hsueh S-C, Lee W-S, et al. Cefiderocol: a promising antibiotic against multidrug-resistant Gram-negative bacteria. Expert Rev Anti Infect Ther. 2019;17(5):307–309.
   PubMed Web of Science ®Google Scholar
• Shields RK. Case Commentary: the need for cefiderocol is clear, but are the supporting clinical data? Antimicrob Agents Chemother. 2020;64(4):1–4.
   Google Scholar
• Stevens RW, Clancy M. Compassionate Use of cefiderocol in the treatment of an intraabdominal Infection Due to multidrug‐resistant Pseudomonas aeruginosa: a case report. Pharmacotherapy. 2019;39(11):1113–1118.
   PubMed Web of Science ®Google Scholar
• Wunderink RG, Matsunaga Y, Ariyasu M, et al. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2021;21(2):213–225.
   PubMed Web of Science ®Google Scholar
• Barnes MD, Taracila MA, Rutter JD, et al. Deciphering the evolution of cephalosporin resistance to ceftolozane-tazobactam in Pseudomonas aeruginosa. mBio. 2018;9(6):e02085–18.
   PubMedGoogle Scholar
• Zhanel GG, Chung P, Adam H, et al. Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant Gram-negative bacilli. Drugs. 2014;74(1):31–51.
   PubMed Web of Science ®Google Scholar
• Beirão EM, da Silva Rodrigues S, de Andrade TK, et al. Activity of ceftolozane-tazobactam and comparators against Gram-negative bacilli: results from the study for monitoring antimicrobial resistance trends (SMART–Brazil; 2016–2017). Braz J Infect Dis. 2020;24(4):310–321.
   PubMedGoogle Scholar
• O’Neall D, Juhász E, Á T, et al. Ceftazidime–avibactam and ceftolozane–tazobactam susceptibility of multidrug resistant Pseudomonas aeruginosa strains in Hungary. Acta Microbiol Immunol Hung. 2020;67(1):61–65.
   PubMedGoogle Scholar
• Alqaid A, Dougherty C, Ahmad S. Triple antibiotic therapy with ceftolozane/tazobactam, colistin and rifampin for pan-resistant Pseudomonas aeruginosa ventilator-associated pneumonia. The Southwest Respir Crit Care Chron. 2015;3(11):35–39.
   Google Scholar
• Rigatto MH, Vieira FJ, Antochevis LC, et al. Polymyxin B in combination with antimicrobials lacking in vitro activity versus polymyxin B in monotherapy in critically ill patients with Acinetobacter baumannii or Pseudomonas aeruginosa infections. Antimicrob Agents Chemother. 2015;59(10):6575–6580.
   PubMed Web of Science ®Google Scholar
• Schmid A, Wolfensberger A, Nemeth J, et al. Monotherapy versus combination therapy for multidrug-resistant Gram-negative infections: systematic review and meta-analysis. Sci Rep. 2019;9(1):1–11.
   PubMedGoogle Scholar
• Linden PK, Kusne S, Coley K, et al. Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa. Clin Infect Dis. 2003;37(11):e154–e60.
   PubMed Web of Science ®Google Scholar
• Furtado GHC, d’Azevedo PA, Santos AF, et al. Intravenous polymyxin B for the treatment of nosocomial pneumonia caused by multidrug-resistant Pseudomonas aeruginosa. Int J Antimicrob Agents. 2007;30(4):315–319.
   PubMed Web of Science ®Google Scholar
• Kallel H, Bahloul M, Hergafi L, et al. Colistin as a salvage therapy for nosocomial infections caused by multidrug-resistant bacteria in the ICU. Int J Antimicrob Agents. 2006;28(4):366–369.
   PubMedGoogle Scholar
• Markou N, Apostolakos H, Koumoudiou C, et al. Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients. Crit Care. 2003;7(5):1–6.
   PubMedGoogle Scholar
• Reina R, Estenssoro E, Sáenz G, et al. Safety and efficacy of colistin in Acinetobacter and Pseudomonas infections: a prospective cohort study. Intensive Care Med. 2005;31(8):1058–1065.
   PubMed Web of Science ®Google Scholar
• Meng Q, Lin F, Ling B. In vitro activity of peptide antibiotics in combination with other antimicrobials on extensively drug-resistant Acinetobacter baumannii in the planktonic and biofilm cell. Front Pharmacol. 2022;13:890955.
   PubMedGoogle Scholar
• Zhang H, Zhu Y, Yang N, et al. In vitro and in vivo activity of combinations of polymyxin B with other antimicrobials against carbapenem-resistant Acinetobacter baumannii. Infect Drug Resist. 2021;14:4657.
   PubMed Web of Science ®Google Scholar
• Hornsey M, Wareham D. In vivo efficacy of glycopeptide-colistin combination therapies in a Galleria mellonella model of Acinetobacter baumannii infection. Antimicrob Agents Chemother. 2011;55(7):3534–3537.
   PubMed Web of Science ®Google Scholar
• Oleksiuk LM, Nguyen MH, Press EG, et al. In vitro responses of Acinetobacter baumannii to two-and three-drug combinations following exposure to colistin and doripenem. Antimicrob Agents Chemother. 2014;58(2):1195–1199.
   PubMedGoogle Scholar
• Li J, Fu Y, Zhang J, et al. The efficacy of colistin monotherapy versus combination therapy with other antimicrobials against carbapenem-resistant Acinetobacter baumannii ST2 isolates. J Chemother. 2020;32(7):359–367.
   PubMedGoogle Scholar
• Soudeiha MA, Dahdouh EA, Azar E, et al. In vitro evaluation of the colistin-carbapenem combination in clinical isolates of A. baumannii using the checkerboard, Etest, and time-kill curve techniques. Front Cell Infect Microbiol. 2017;7:209.
   PubMed Web of Science ®Google Scholar
• Shields RK, Kwak EJ, Potoski BA, et al. High mortality rates among solid organ transplant recipients infected with extensively drug-resistant Acinetobacter baumannii: using in vitro antibiotic combination testing to identify the combination of a carbapenem and colistin as an effective treatment regimen. Diagn Microbiol Infect Dis. 2011;70(2):246–452.
   PubMed Web of Science ®Google Scholar
• Vidaillac C, Benichou L, Duval RE. In vitro synergy of colistin combinations against colistin-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae isolates. Antimicrob Agents Chemother. 2012;56(9):4856–4861.
   PubMed Web of Science ®Google Scholar
• Fan B, Guan J, Wang X, et al. Activity of colistin in combination with meropenem, tigecycline, fosfomycin, fusidic acid, rifampin or sulbactam against extensively drug-resistant Acinetobacter baumannii in a murine thigh-infection model. PLoS One. 2016;11(6):e0157757.
   PubMed Web of Science ®Google Scholar
• Yilmaz EM, Sunbul M, Aksoy A, et al. Efficacy of tigecycline/colistin combination in a pneumonia model caused by extensively drug-resistant Acinetobacter baumannii. Int J Antimicrob Agents. 2012;40(4):332–336.
   PubMedGoogle Scholar
• Bowers DR, Cao H, Zhou J, et al. Assessment of minocycline and polymyxin B combination against Acinetobacter baumannii. Antimicrob Agents Chemother. 2015;59(5):2720–2725.
   PubMed Web of Science ®Google Scholar
• Cheng A, Chuang Y-C, Sun H-Y, et al. Excess mortality associated with colistin-tigecycline compared with colistin-carbapenem combination therapy for extensively drug-resistant Acinetobacter baumannii bacteremia: a multicenter prospective observational study. Crit Care Med. 2015;43(6):1194–1204.
   PubMed Web of Science ®Google Scholar
• Sharma R, Park TE, Moy S. Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination for the treatment of resistant Gram-negative organisms. Clin Ther. 2016;38(3):431–444.
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Lawrence CK, Adam H, et al. Imipenem–relebactam and meropenem–vaborbactam: two novel carbapenem-β-lactamase inhibitor combinations. Drugs. 2018;78(1):65–98.
   PubMed Web of Science ®Google Scholar
• Hsueh S-C, Lee Y-J, Huang Y-T, et al. In vitro activities of cefiderocol, ceftolozane/ tazobactam,ceftazidime/avibactam and other comparative drugs against imipenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and Stenotrophomonas maltophilia, all associated with bloodstream infections in Taiwan. J Antimicrob Chemother. 2019;74(2):380–386.
   PubMed Web of Science ®Google Scholar
• Stainton SM, Monogue ML, Tsuji M, et al. Efficacy of humanized cefiderocol exposures over 72 hours against a diverse group of Gram-negative isolates in the neutropenic murine thigh infection model. Antimicrob Agents Chemother. 2019;63(2):e01040–18.
   PubMedGoogle Scholar
• Portsmouth S, van Veenhuyzen D, Echols R, et al. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial. Lancet Infect Dis. 2018;18(12):1319–1328.
   PubMed Web of Science ®Google Scholar
• Shields RK, Clancy CJ, Gillis LM, et al. Epidemiology, clinical characteristics and outcomes of extensively drug-resistant Acinetobacter baumannii infections among solid organ transplant recipients. PLoS One. 2012;7(12):e52349.
   PubMed Web of Science ®Google Scholar
• Park SY, Si HJ, Eom JS, et al. Survival of carbapenem-resistant Acinetobacter baumannii bacteremia: colistin monotherapy versus colistin plus meropenem. Int J Med Res. 2019;47(12):5977–5985.
   PubMedGoogle Scholar
• Yilmaz GR, Guven T, Guner R, et al. Colistin alone or combined with sulbactam or carbapenem against A. baumannii in ventilator-associated pneumonia. J Infect Dev Ctries. 2015;9(5):476–485.
   PubMedGoogle Scholar
• Khawcharoenporn T, Pruetpongpun N, Tiamsak P, et al. Colistin-based treatment for extensively drug-resistant Acinetobacter baumannii pneumonia. Int J Antimicrob Agents. 2014;43(4):378–382.
   PubMed Web of Science ®Google Scholar
• Katip W, Uitrakul S, Oberdorfer P. A comparison of colistin versus colistin plus meropenem for the treatment of carbapenem-resistant Acinetobacter baumannii in critically ill patients: a propensity score-matched analysis. Antibiotics. 2020;9(10):647.
   Google Scholar
• Qureshi ZA, Hittle LE, O’Hara JA, et al. Colistin-resistant Acinetobacter baumannii: beyond carbapenem resistance. Clinil Infecti Dis. 2015;60(9):1295–1303.
   PubMed Web of Science ®Google Scholar
• Petrosillo N, Giannella M, Antonelli M, et al. Clinical experience of colistin-glycopeptide combination in critically ill patients infected with Gram-negative bacteria. Antimicrob Agents Chemother. 2014;58(2):851–858.
   PubMed Web of Science ®Google Scholar
• Wareham D, Gordon N, Hornsey M. In vitro activity of teicoplanin combined with colistin versus multidrug-resistant strains of Acinetobacter baumannii. J Antimicrob Chemother. 2011;66(5):1047–1051.
   PubMed Web of Science ®Google Scholar
• Hornsey M, Longshaw C, Phee L, et al. In vitro activity of telavancin in combination with colistin versus Gram-negative bacterial pathogens. Antimicrob Agents Chemother. 2012;56(6):3080–3085.
   PubMed Web of Science ®Google Scholar
• Pogue JM, Kaye KS. Is there really no benefit to combination therapy with colistin? Expert Rev Anti Infect Ther. 2013;11(9):881–884.
   PubMed Web of Science ®Google Scholar
• Chen Z, Chen Y, Fang Y, et al. Meta-analysis of colistin for the treatment of Acinetobacter baumannii infection. Sci Rep. 2015;5(1):1–8.
   Web of Science ®Google Scholar
• Cheng I, Chen Y-H, Lai -C-C. Intravenous colistin monotherapy versus combination therapy against carbapenem-resistant Gram-negative bacteria infections: meta-analysis of randomized controlled trials. J Cin Med. 2018;7(8):208.
   Google Scholar
• Ni W, Shao X, Di X, et al. In vitro synergy of polymyxins with other antibiotics for Acinetobacter baumannii: a systematic review and meta-analysis. Int J Antimicrob Agents. 2015;45(1):8–18.
   PubMed Web of Science ®Google Scholar
• Nation RL, Garonzik SM, Thamlikitkul V, et al. Dosing guidance for intravenous colistin in critically ill patients. Clin Infect Dis. 2017;64(5):565–571.
   PubMed Web of Science ®Google Scholar